Muscle-Targeting Complexes for DMPK Silencing in DM1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myotonic dystrophy type 1 (DM1) are ineffective, and there is a challenge in effectively targeting muscle cells to deliver molecular payloads that inhibit the expression or activity of the DMPK allele with expanded disease-associated repeats.
Innovation Solution
Development of muscle-targeting complexes comprising muscle-targeting agents, such as antibodies, that specifically bind to the transferrin receptor on muscle cells, allowing for receptor-mediated internalization and release of molecular payloads, like oligonucleotides, to inhibit DMPK expression or activity within the cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for myotonic dystrophy type 1, then treatment is provided, but the therapies are ineffective in reducing DMPK expression levels in muscle tissues
Solution Approach 1:
The patent uses transferrin receptor-mediated endocytosis as an intermediary mechanism to deliver molecular payloads into muscle cells. The complexes exploit the natural cellular uptake pathway of the transferrin receptor to bypass delivery barriers, allowing effective entry of therapeutic oligonucleotides into muscle cells without requiring direct cell penetration or invasive methods.
2Manufacturing precision
If molecular payloads are delivered without targeting, then delivery is simple, but the payloads cannot specifically inhibit DMPK expression in muscle cells
Solution Approach 1:
The therapeutic complex is segmented into distinct functional components: a targeting moiety (transferrin or anti-transferrin receptor antibody) and a molecular payload (oligonucleotide). This segmentation allows each component to perform its specialized function - the targeting moiety provides muscle cell specificity through transferrin receptor binding, while the payload provides DMPK inhibition - and simplifies the overall design compared to creating a completely new targeted delivery system.
3Manufacturing precision
If muscle-targeting complexes are developed with high specificity, then DMPK expression is effectively reduced in muscle tissues, but the complexity of the complex increases
Solution Approach 1:
The transferrin receptor serves as a universal target that is overexpressed on muscle cells and can be exploited by multiple different targeting moieties (transferrin, anti-transferrin receptor antibodies). This universality allows the same receptor to be used for delivering various therapeutic payloads to muscle cells, reducing the need to develop entirely new targeting systems for different therapies and effectively lowering overall complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes effectively reduce DMPK expression levels in muscle tissues, providing a potential therapeutic approach for myotonic dystrophy by inhibiting the toxic effects of disease-associated DMPK alleles.
Implementation Method 1
the complexes are taken up into the cells via a receptor mediated internalization
Data Source
AI summary
Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of a DMPK allele comprising a disease-associated-repeat. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.